SYSTIMMUNE
SystImmune is a biopharmaceutical company. It is focused on the treatment of cancer through developing novel therapeutic bi-specific, and multi-specific antibodies, as well as antibody-drug conjugates. They are highly experienced immuno-oncology scientists utilizing several technology platforms to develop world-class advanced antibody-based drug therapies.
SYSTIMMUNE
Social Links:
Industry:
Biopharma Biotechnology Professional Services
Founded:
2014-01-01
Address:
Redmond, Washington, United States
Country:
United States
Website Url:
http://www.systimmune.com
Total Employee:
11+
Status:
Active
Contact:
+1 425 453 6841
Email Addresses:
[email protected]
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon Google Font API Google Analytics Google Maps SSL By Default IPv6 Cloudflare Hosting
Similar Organizations
Boston Pharmaceuticals
Boston Pharmaceuticals Provides Healthcare Services.
Enterin
Philadelphia-based biotechnology company .
Genosco
Genosco is a biotechnology company.
Sustinent
Sustinent is a biotechnology company.
Transpire Bio
Transpire Bio is a biotechnology platform.
Official Site Inspections
http://www.systimmune.com Semrush global rank: 5.4 M Semrush visits lastest month: 1.38 K
- Host name: 172.67.212.241
- IP address: 172.67.212.241
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "SystImmune"
SystImmune, Inc.
SystImmune Inc. is a biopharmaceutical company focused on developing novel therapeutic bi-specific, and multi-specific antibodies, as well as antibody-drug conjugates (ADCs) for the …See details»
SystImmune - Crunchbase Company Profile & Funding
Organization. SystImmune . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. About. SystImmune is a …See details»
SystImmune Management Team | Org Chart - RocketReach
Top SystImmune Management Employees Jie D'Elia Chief Executive Officer at SystImmune Princeton, NJ, US View. 2 yahoo.com; systimmune.com; 2 425502XXXX; 425985XXXX; Le …See details»
SystImmune - LinkedIn
SystImmune | 18,164 followers on LinkedIn. Located in Redmond WA, founded in 2014, Systimmune Inc. is a bio-pharmaceutical company focused on the treatment of cancer through developing novel ...See details»
SystImmune Company Profile | Management and Employees List
SystImmune, Inc. is a biopharmaceutical company specializing in the development of novel therapeutic bi-specific and multi-specific antibodies, as well as antibody-drug conjugates …See details»
SystImmune Information - RocketReach
Located in Redmond WA, founded in 2014, Systimmune Inc. is a bio-pharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and tri …See details»
Leaders in Breast and Lung Cancer treatment join SystImmune
SystImmune also developed the first-in-class bi-specific ADC drug platform. Currently, the company has eight molecules in Phase I or II oncology clinical trials in China, including SI …See details»
SYSTIMMUNE INC. Company Profile | Redmond, WA - Dun
Find company research, competitor information, contact details & financial data for SYSTIMMUNE INC. of Redmond, WA. Get the latest business insights from Dun & Bradstreet.See details»
Systimmune - VentureRadar
Systimmune Inc. is a bio-pharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and tri-specific antibodies, as well as antibody-drug …See details»
Systimmune Company Profile -Sales, Contacts, Competitors – …
Systimmune is located in Redmond, Washington. This organization primarily operates in the Pharmaceutical Preparations business / industry within the Chemicals and Allied Products …See details»
SystImmune - LifeScienceHistory.com
Systimmune.com. 15318 NE 95th Street. Redmond, WA 98052. Company Info Phone (425) 453-6841 Year Established 2014. Contacts Yi Zhu CEO. Company Description. SystImmune is a …See details»
Systimmune 2025 Company Profile: Valuation, Investors
Systimmune General Information Description. Operator of a biopharmaceutical company intended to develop antibody-based drug therapies. The company aims to offer novel therapeutic bi …See details»
SystImmune - Org Chart, Teams, Culture & Jobs | The Org
View SystImmune's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more. This is an unverified company page.See details»
Systimmune, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Systimmune, Inc. with its drug pipeline, therapeutic area, technology platform, 23 clinical trials, 209 news, and 4 literature, Disease Domain:Neoplasms, Endocrinology and Metabolic …See details»
SystImmune Company Profile - Office Locations, Competitors
SystImmune has 5 employees at their 1 location and $76 m in total funding,. See insights on SystImmune including office locations, competitors, revenue, financials, executives, …See details»
SystImmune, Inc. Announces FDA Clearance of IND Application for …
Redmond, WA – November 8 th, 2024 – SystImmune, Inc (SystImmune), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has …See details»
SystImmune - Overview, News & Similar companies | ZoomInfo.com
Systimmune Inc., located in Redmond, Washington, is a clinical stage immune-oncology biopharmaceutical company focused on the development of multi-specific antibody …See details»
Leaders in Breast and Lung Cancer treatment join SystImmune
Apr 26, 2023 SystImmune, Inc. to Present New BL-B01D1 Data in Urothelial, Biliary Tract, and Esophageal Squamous Cell Carcinoma at ESMO Congress 2024 Sep 9, 2024See details»
SystImmune, Inc. to Present New Data from Oncology Programs at …
May 1, 2023 SystImmune is a clinical-stage biopharmaceutical company located in Redmond, WA. It specializes in developing innovative cancer treatments using its established drug …See details»
SystImmune spreads into first-line lung | ApexOnco - Clinical Trials ...
Feb 24, 2025 SystImmune’s Bristol Myers Squibb-partnered ADC izalontamab brengitecan is already in a raft of Chinese phase 3 trials, and now first-line NSCLC is joining the roster, a …See details»